Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Virchows Archiv
Erschienen in: Virchows Archiv 6/2015

01.12.2015 | Review and Perspectives

Chronic inflammation in urothelial bladder cancer

verfasst von: Gabriella Nesi, Stefania Nobili, Tommaso Cai, Saverio Caini, Raffaella Santi

Erschienen in: Virchows Archiv | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

The association between inflammation and cancer has been pointed out in epidemiological and clinical studies, revealing how chronic inflammation may contribute to carcinogenesis in various malignancies. However, the molecular events leading to malignant transformation in a chronically inflamed environment are not fully understood. In urothelial carcinoma of the urinary bladder, inflammation plays a dual role. On the one hand, chronic inflammation is a well-established risk factor for the development of bladder cancer (BC), as seen in Schistosoma haematobium infection. On the other, intravesical therapy by bacillus Calmette-Guérin (BCG), which induces inflammation, offers protection against cancer recurrence. The large variety of pro-inflammatory mediators expressed by BC and immune cells binds to specific receptors which control signalling pathways. These activate transcription of a plethora of downstream factors. This review summarizes recent data regarding inflammation and urothelial carcinoma, with special emphasis on the role the inflammatory response plays in BC recurrence risk and progression.
Literatur
1.
Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X (2005) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23:5746–5756PubMedCrossRef
2.
Virchow R (1863) Cellular pathology as based upon physiological and pathological histology. J. B. Lippincott, Philadelphia
3.
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef
4.
Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, Sica A (2009) Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214:761–777PubMedCrossRef
5.
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef
6.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:e359–e386PubMedCrossRef
7.
8.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Bladder Cancer V. I 2015
9.
Scosyrev E, Noyes K, Feng C, Messing E (2009) Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115:68–74PubMedCrossRef
10.
International Agency for Research on Cancer (2011) Monographs on the evaluation of carcinogenic risks to humans. A review of carcinogen—part B: biological agents. International Agency for Research on Cancer, Lyon
11.
Brandau S, Suttmann H (2007) Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 61:299–305PubMedCrossRef
12.
Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H (2013) Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 104:22–27PubMedCrossRef
13.
Fried B, Reddy A, Mayer D (2011) Helminths in human carcinogenesis. Cancer Lett 305:239–249PubMedCrossRef
14.
Abol-Enein H (2008) Infection: is it a cause of bladder cancer. Scand J Urol Nephrol 218(Suppl):79–84CrossRef
15.
Badawi AF (1996) Molecular and genetic events in schistosomiasis-associated human bladder cancer: role of oncogenes and tumor suppressor genes. Cancer Lett 105:123–138PubMedCrossRef
16.
Rosin MP, Anwar WA, Ward AJ (1994) Inflammation, chromosomal instability, and cancer: the schistosomiasis model. Cancer Res 54(Suppl):1929s–1933sPubMed
17.
Mostafa MH, Sheweita SA, O’Connor PJ (1999) Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev 12:97–111PubMedCentralPubMed
18.
Botelho MC, Oliveira PA, Lopes C, Correia da Costa JM, Machado JC (2011) Urothelial dysplasia and inflammation induced by Schistosoma haematobium total antigen instillation in mice normal urothelium. Urol Oncol 29:809–814PubMedCrossRef
19.
Botelho MC, Machado JC, da Costa JM (2010) Schistosoma haematobium and bladder cancer: what lies beneath? Virulence 1:84–87PubMedCrossRef
20.
Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni Jr JF (1984) Urinary tract infection and risk of bladder cancer. Am J Epidemiol 119:510–515PubMed
21.
Vermeulen SH, Hanum N, Grotenhuis AJ, Castano-Vinyals G, van der Heijden AG, Aben KK, Mysorekar IU, Kiemeney LA (2015) Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. Br J Cancer 112:594–600PubMedCrossRef
22.
Dhakal BK, Kulesus RR, Mulvey MA (2008) Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli. Eur J Clin Investig 38(Suppl 2):2–11 See comment in PubMed Commons belowCrossRef
23.
Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ (2010) Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 6:e1001042PubMedCentralPubMedCrossRef
24.
Song J, Abraham SN (2008) Innate and adaptive immune responses in the urinary tract. Eur J Clin Investig 38(Suppl 2):21–28CrossRef
25.
Aquilina G, Bignami M (2001) Mismatch repair in correction of replication errors and processing of DNA damage. J Cell Physiol 187:145–154PubMedCrossRef
26.
Jiang X, Castelao JE, Groshen S, Cortessis VK, Shibata D, Conti DV, Yuan JM, Pike MC, Gago-Dominguez M (2009) Urinary tract infections and reduced risk of bladder cancer in Los Angeles. Br J Cancer 100:834–839PubMedCentralPubMedCrossRef
27.
Zur Hausen H (2009) Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384:260–265PubMedCrossRef
28.
Li N, Yang L, Zhang Y, Zhao P, Zheng T, Dai M (2011) Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis 204:217–223PubMedCentralPubMedCrossRef
29.
Cai T, Mazzoli S, Meacci F, Nesi G, Geppetti P, Malossini G, Bartoletti R (2011) Human papillomavirus and non-muscle invasive urothelial bladder cancer: potential relationship from a pilot study. Oncol Rep 25:485–489PubMedCrossRef
30.
Shigehara K, Sasagawa T, Kawaguchi S, Nakashima T, Shimamura M, Maeda Y, Konaka H, Mizokami A, Koh E, Namiki M (2011) Etiologic role of human papillomavirus infection in bladder carcinoma. Cancer 117:2067–2076PubMedCrossRef
31.
Alexander RE, Davidson DD, Lopez-Beltran A, Montironi R, MacLennan GT, Comperat E, Idrees MT, Emerson RE, Cheng L (2013) Human papillomavirus is not an etiologic agent of urothelial inverted papillomas. Am J Surg Pathol 37:1223–1228PubMedCrossRef
32.
Youshya S, Purdie K, Breuer J, Proby C, Sheaf MT, Oliver RT, Baithun S (2005) Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. J Clin Pathol 58:207–210PubMedCentralPubMedCrossRef
33.
Lehoux M, D’Abramo CM, Archambault J (2009) Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics 12:268–280PubMedCentralPubMedCrossRef
34.
Alexander RE, Hu Y, Kum JB, Montironi R, Lopez-Beltran A, MacLennan GT, Idrees MT, Emerson RE, Ulbright TM, Grignon DG, Eble JN, Cheng L (2012) p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Mod Pathol 25:1526–1533PubMedCrossRef
35.
Kim SH, Joung JY, Chung J, Park WS, Lee KH, Seo HK (2014) Detection of human papillomavirus infection and p16 immunohistochemistry expression in bladder cancer with squamous differentiation. PLoS One 9:e93525PubMedCentralPubMedCrossRef
36.
Clouston D, Lawrentschuk N (2013) Metaplastic conditions of the bladder. BJU Int 112(Suppl 2):27–31PubMedCrossRef
37.
Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman RF (2002) Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil 83:346–351PubMedCrossRef
38.
Kalisvaart JF, Katsumi HK, Ronningen LD, Hovey RM (2010) Bladder cancer in spinal cord injury patients. Spinal Cord 48:257–261PubMedCrossRef
39.
West DA, Cummings JM, Longo WE, Virgo KS, Johnson FE, Parra RO (1999) Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury. Urology 53:292–297PubMedCrossRef
40.
Lee WY, Sun LM, Lin CL, Liang JA, Chang YJ, Sung FC, Kao CH (2014) Risk of prostate and bladder cancers in patients with spinal cord injury: a population-based cohort study. Urol Oncol 32(51):e1–e7PubMedCrossRef
41.
Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254–265PubMedCrossRef
42.
43.
Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G, Nagasue N (2003) The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 23:5015–5022PubMed
44.
Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 23:8959–8967PubMedCrossRef
45.
Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R (2007) High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13:1472–1479PubMedCrossRef
46.
Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A (2008) Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV non-small cell lung cancer. Cancer 113:1387–1395PubMedCrossRef
47.
Dufresne M, Dumas G, Asselin E, Carrier C, Pouliot M, Reyes-Moreno C (2011) Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells. Mol Immunol 48:1556–1567PubMedCrossRef
48.
Yang H, Kim C, Mj K, Schwendener RA, Alitalo K, Heston W, Kim I, Kim WJ, Koh GY (2011) Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer 10:36PubMedCentralPubMedCrossRef
49.
Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y (2000) Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 7:263–269PubMedCrossRef
50.
Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N (2009) Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 181:1894–1900PubMedCrossRef
51.
Ayari C, LaRue H, Hovington H, Caron A, Bergeron A, Tetu B, Fradet V, Fradet Y (2013) High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer. Hum Pathol 44:1630–1637PubMedCrossRef
52.
Masson-Lecomte A, Rava M, Real FX, Hartmann A, Allory Y, Malats N (2014) Inflammatory biomarkers and bladder cancer prognosis: a systematic review. Eur Urol 66:1078–1091PubMedCrossRef
53.
Marx J (2008) Cancer immunology. Cancer’s bulwark against immune attack: MDS cells. Science 319:154–156PubMedCrossRef
54.
Eruslanov E, Daurkin I, Vieweg J, Daaka Y, Kusmartsev S (2011) Aberrant PGE2 metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int Immunopharmacol 11:848–855PubMedCentralPubMedCrossRef
55.
Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, Albelda SM (2010) Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 18:1947–1959PubMedCentralPubMedCrossRef
56.
Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 7:10PubMedCentralPubMed
57.
Winerdal ME, Marits P, Winerdal M, Rosenblatt R, Tolf A, Selling K, Sherif A, Winqvist O (2011) FOXP3 and survival in urinary bladder cancer. BJU Int 108:1672–1678PubMedCrossRef
58.
Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E (2007) CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104:3967–3972PubMedCentralPubMedCrossRef
59.
Krpina K, Babarovic E, Dordevic G, Fuckar Z, Jonjic N (2012) The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytes. Croat Med J 53:598–604PubMedCentralPubMedCrossRef
60.
Chi LJ, Lu HT, LiGL WXM, Su Y, Xu WH, Shen BZ (2010) Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clin Exp Immunol 161:480–489PubMedCentralPubMedCrossRef
61.
Lee SJ, Park SS, Lee US, Kim WJ, Moon SK (2008) Signaling pathway for TNF-alpha-induced MMP-9 expression: mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells. Int Immunopharmacol 8:1821–1826PubMedCrossRef
62.
Feng CC, Wang PH, Ding Q, Guan M, Zhang YF, Jiang HW, Wen H, Wu Z (2013) Expression of pigment epithelium-derived factor and tumor necrosis factor-alpha is correlated in bladder tumor and is related to tumor angiogenesis. Urol Oncol 31:241–246PubMedCrossRef
63.
Tsui KH, Wang SW, Chung LC, Feng TH, Lee TY, Chang PL, Juang HH (2013) Mechanisms by which interleukin-6 attenuates cell invasion and tumorigenesis in human bladder carcinoma cells. Biomed Res Int 2013:791212PubMedCentralPubMedCrossRef
64.
Chen MF, Lin PY, Wu CF, Chen WC, Wu CT (2013) IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One 8:e61901PubMedCentralPubMedCrossRef
65.
Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomark Prev 15:381–384CrossRef
66.
Gakis G, Todenhöfer T, Renninger M, Schilling D, Sievert KD, Schwentner C, Stenzl A (2011) Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 108:1800–1805PubMedCrossRef
67.
Wu CC1, Huang YK, Chung CJ, Huang CY, Pu YS, Shiue HS, Lai LA, Lin YC, Su CT, Hsueh YM (2013) Polymorphism of inflammatory genes and arsenic methylation capacity are associated with urothelial carcinoma. Toxicol Appl Pharmacol 272:30–36PubMedCrossRef
68.
Pignot G, Bieche I, Vacher S, Güet C, Vieillefond A, Debré B, Lidereau R, Amsellem-Ouazana D (2009) Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur Urol 56:678–688PubMedCrossRef
69.
Sheryka E1, Wheeler MA, Hausladen DA, Weiss RM (2003) Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 62:162–166PubMedCrossRef
70.
Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP (2000) Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 60:2290–2299PubMed
71.
Reis ST, Leite KR, Piovesan LF, Pontes-Junior J, Viana NI, Abe DK, Crippa A, Moura CM, Adonias SP, Srougi M, Dall’Oglio MF (2012) Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of bladder cancer. BMC Urol 12:18PubMedCentralPubMedCrossRef
72.
Bukan N, Sözen S, Coskun U, Sancak B, Günel N, Bozkirli I, Senocak C (2003) Serum interleukin-18 and nitric oxide activity in bladder carcinoma. Eur Cytokine Netw 14:163–167PubMed
73.
74.
Miyake M1, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, Rosser CJ (2013) Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. BMC Cancer 13:322PubMedCentralPubMedCrossRef
75.
Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR (2005) Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 97:1840–1847PubMedCrossRef
76.
Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS (2005) Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23:2744–2753PubMedCrossRef
77.
Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R, Basik M (2006) The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97:275–283PubMedCrossRef
78.
Nishizawa K, Nishiyama H, Oishi S, Tanahara N, Kotani H, Mikami Y, Toda Y, Evans BJ, Peiper SC, Saito R, Watanabe J, Fujii N, Ogawa O (2010) Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4. Int J Cancer 127:1180–1187PubMedCrossRef
79.
Batsi O, Giannopoulou I, Nesseris I, Valavanis C, Gakiopoulou H, Patsouris ES, Arapandoni-Dadioti P, Lazaris AC (2014) Immunohistochemical evaluation of CXCL12-CXCR4 axis and VEGFR3 expression in primary urothelial cancer and its recurrence. Anticancer Res 34:3537–3542PubMed
80.
Hao M1, Zheng J, Hou K, Wang J, Chen X, Lu X, Bo J, Xu C, Shen K, Wang J (2012) Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem Pharmacol 84:204–214PubMedCrossRef
81.
Margulis V, Shariat SF, Ashfaq R, Thompson M, Sagalowsky AI, Hsieh JT, Lotan Y (2007) Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol 177:1163–1168PubMedCrossRef
82.
Tadin T, Krpina K, Stifter S, Babarović E, Fučkar Z, Jonjić N (2012) Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma. Diagn Pathol 7:152PubMedCentralPubMedCrossRef
83.
van der Horst G, Bos L, van der Pluijm G (2012) Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res 10:995–1009PubMedCrossRef
84.
Thanan R, Murata M, Ma N, Hammam O, Wishahi M, El Leithy T, Hiraku Y, Oikawa S, Kawanishi S (2012) Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer. Mediat Inflamm 2012:165,879CrossRef
85.
Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377–386PubMedCrossRef
86.
Tomlinson DC, Baxter EW, Loadman PM, Hull MA, Knowles MA (2012) FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms. PLoS One 7:e38972PubMedCentralPubMedCrossRef
87.
Shi Y, Cui L, Dai G, Chen J, Pan H, Song L, Cheng S, Wang X (2006) Elevated prostaglandin E2 level via cPLA2–COX-2–mPGES-1 pathway involved in bladder carcinogenesis induced by terephthalic acid-calculi in Wistar rats. Prostaglandins Leukot Essent Fat Acids 74:309–315CrossRef
88.
Wheeler MA, Hausladen DA, Yoon JH, Weiss RM (2002) Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. J Urol 168:1568–1573PubMedCrossRef
89.
von der Emde L, Goltz D, Latz S, Müller SC, Kristiansen G, Ellinger J, Syring I (2014) Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer. Am J Cancer Res 4:952–962PubMedCentralPubMed
90.
Ehsan A, Sommer F, Schmidt A, Klotz T, Koslowski J, Niggemann S, Jacobs G, Engelmann U, Addicks K, Bloch W (2002) Nitric oxide pathways in human bladder carcinoma. The distribution of nitric oxide synthases, soluble guanylyl cyclase, cyclic guanosine monophosphate, and nitrotyrosine. Cancer 95:2293–2301PubMedCrossRef
91.
Gecit I, Aslan M, Gunes M, Pirincci N, Esen R, Demir H, Ceylan K (2012) Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer. J Cancer Res Clin Oncol 138:739–743PubMedCentralPubMedCrossRef
92.
Amasyali AS1, Kucukgergin C, Erdem S, Sanli O, Seckin S, Nane I (2012) Nitric oxide synthase (eNOS4a/b) gene polymorphism is associated with tumor recurrence and progression in superficial bladder cancer cases. J Urol 188:2398–2403PubMedCrossRef
93.
Romih R, Korosec P, Sedmak B, Jezernik K (2008) Mitochondrial localization of nitric oxide synthase in partially differentiated urothelial cells of urinary bladder lesions. Appl Immunohistochem Mol Morphol 16:239–245PubMedCrossRef
94.
Ben-Neriah Y, Karin M (2011) Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12:715–723PubMedCrossRef
95.
96.
Vendramini-Costa DB, Carvalho JE (2012) Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18:3831–3852PubMedCrossRef
97.
Oeckinghaus A, Hayden MS, Sankar Ghosh S (2011) Crosstalk in NF-kB signaling pathways. Nat Immunol 12:695–708PubMedCrossRef
98.
Levidou G, Saetta AA, Korkolopoulou P, Papanastasiou P, Gioti K, Pavlopoulos P, Diamantopoulou K, Thomas-Tsagli E, Xiromeritis K, Patsouris E (2008) Clinical significance of nuclear factor (NF)-kappaB levels in urothelial carcinoma of the urinary bladder. Virchows Arch 452:295–304PubMedCrossRef
99.
Kontos S1, Kominea A, Melachrinou M, Balampani E, Sotiropoulou-Bonikou G (2010) Inverse expression of estrogen receptor-beta and nuclear factor-kappaB in urinary bladder carcinogenesis. Int J Urol 17:801–809PubMedCrossRef
100.
Duan W, Wang E, Zhang F, Wang T, You X, Qiao B (2014) Association between the NFKB1-94ins/del ATTG polymorphism and cancer risk: an updated meta-analysis. Cancer Investig 32:311–320CrossRef
101.
Riemann K, Becker L, Struwe H, Rübben H, Eisenhardt A, Siffert W (2007) Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 45:423–430PubMedCrossRef
102.
Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206:1457–1464PubMedCentralPubMedCrossRef
103.
Qi QR, Yang ZM (2014) Regulation and function of signal transducer and activator of transcription 3. World J Biol Chem 5:231–239PubMedCentralPubMed
104.
Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15:283–293PubMedCentralPubMedCrossRef
105.
Zhang B, Lu Z, Hou Y, Hu J, Wang C (2014) The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells. Tumour Biol 35:5401–5407PubMedCrossRef
106.
Degoricija M1, Situm M, Korać J, Miljković A, Matić K, Paradžik M, Marinović Terzić I, Jerončić A, Tomić S, Terzić J (2014) High NF-κB and STAT3 activity in human urothelial carcinoma: a pilot study. World J Urol 32:1469–1475PubMedCrossRef
107.
Ho PL, Lay EJ, Jian W, Parra D, Chan KS (2012) Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res 72:3135–3142PubMedCentralPubMedCrossRef
108.
Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180–183PubMed
109.
110.
Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev Urol 11:153–162PubMedCrossRef
111.
Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See W (2014) Loss of bacillus Calmette-Guérin viability adversely affects the direct response of urothelial carcinoma cells to bacillus Calmette-Guérin exposure. J Urol 191:823–829PubMedCrossRef
112.
Zuiverloon TC, Nieuweboer AJ, Vékony H, Kirkels WJ, Bangma CH, Zwarthoff EC (2012) Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61:128–145PubMedCrossRef
113.
Cai T, Nesi G, Mazzoli S, Meacci F, Tinacci G, Luciani LG, Ficarra V, Malossini G, Bartoletti R (2012) Prediction of response to bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio. Exp Ther Med 4:459–464PubMedCentralPubMed
114.
Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A, Montironi R, Santini D, Cheng L, Martignoni G, Cascinu S, Tortora G (2015) The route to personalized medicine in bladder cancer: where do we stand? Target Oncol. doi:10.​1007/​s11523-015-0357-x
115.
Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, Stewart JC, Zheng R, Loman RA, Foster RS, Knapp DW (2010) Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther 9:1371–1377PubMedCentralPubMedCrossRef
116.
Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, De la Cerda J, Eagle C, Viner JL, Palmer JL, Lerner SP (2011) A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res 4:1580–1589CrossRef
117.
118.
Sonpavde G, Rosser CJ, Pan C-X, Parikh RA, Nix J, Gingrich JR, Hernandez L, Huang B-Y, Wong HC (2015) Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC). J Clin Oncol 33:e15509
Metadaten
Titel
Chronic inflammation in urothelial bladder cancer
verfasst von
Gabriella Nesi
Stefania Nobili
Tommaso Cai
Saverio Caini
Raffaella Santi
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 6/2015
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-015-1820-x

Weitere Artikel der Ausgabe 6/2015

Virchows Archiv 6/2015 Zur Ausgabe

Original Article

Potential role of Th17 cells in the pathogenesis of type 2 autoimmune pancreatitis

Original Article

Molecular alterations in malignant blue nevi and related blue lesions

Original Article

Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential

Editorial

In this issue

Original Article

Omental mesenteric myxoid hamartoma, a subtype of inflammatory myofibroblastic tumor? Considerations based on the histopathological evaluation of four cases

Original Article

Reappraisal of sinonasal undifferentiated carcinoma: SMARCB1 (INI1)-deficient sinonasal carcinoma: a single-institution experience

Neu im Fachgebiet Pathologie

Open Access 15.04.2024 | Biomarker | Schwerpunkt: Next Generation Pathology

Molekularpathologische Untersuchungen im Wandel der Zeit

11.04.2024 | Pathologie | Schwerpunkt: Next Generation Pathology

Vergleichende Pathologie in der onkologischen Forschung

Open Access 08.04.2024 | GIST | CME

Gastrointestinale Stromatumoren
Wo stehen wir?

03.04.2024 | Zielgerichtete Therapie | Schwerpunkt: Next Generation Pathology

Personalisierte Medizin in der Onkologie